Workshop: AML mutation detection using error-corrected sequencing

Acute myeloid leukemia (AML) is a clonally heterogeneous cancer where the landscape of mutations is highly variable between children and adults, involving complex chromosomal translocations, indels and single nucleotide variants (SNVs). Traditional molecular assays rely upon multiple platforms to identify mutations but generally lack quantitation of rare clones. Advances in sequencing-based methods enable comprehensive detection of gene fusions, SNVs, gene expression and internal tandem duplications. In this workshop, Dr. Todd Druley, from Washington University, describes his use of error-corrected sequencing coupled with powerful bioinformatics to detect rare clonal variants in adult and pediatric AML.

Webinar: Validation of Error-Corrected Sequencing for Hematological Malignancies

In this webinar, Drs. Catherine Rehder and Sarah Rapisardo, at Duke University, describes their efforts to validate the Archer® VariantPlex® Myeloid assay. They also discuss their work to expand testing with a custom Archer FusionPlex® assay to detect known and novel fusions, with a focus on Ph-like acute lymphoblastic leukemia (ALL) fusions.


Cecilia Yeung, MD., from Fred Hutchinson Cancer Research Center, discusses how she is using Anchored Multiplex PCR (AMP™) technology for rapid identification of fusions in leukemias with Oxford Nanopore™ real-time sequencing. This webinar was recorded on August 7, 2018.

Plasma Mutation Panel

In this AMP 2017 workshop, Dr. Margaret L. Gulley, from UNC School of Medicine, describes her ability to confidently detect variants and viral markers in plasma DNA using targeted NGS coupled with powerful bioinformatics.

FLT3-ITD Detection With Archer Blood Cancer Assays

The molecular landscape of leukemia and lymphoma has expanded exponentially in the last two decades, and the complexity and scope of biomarkers makes molecular analysis difficult for any single approach. Archer FusionPlex and VariantPlex assays are powered by Anchored Multiplex PCR (AMP) target enrichment chemistry to detect multiple mutation types and gene expression profiling in a single sample.

Why RNA is Better for Fusion Detection

Why do Archer FusionPlex assays use RNA instead of DNA for input material? It all comes down to biological relevance, cost, and turn-around time. See why RNA is better for fusion detection than DNA-based hybrid capture techniques.

AMP™ is Better: Strand Specificity

See how Anchored Multiplex PCR (AMP) chemistry is better than traditional opposing primer-based enrichment, because strand-specific priming allows you to identify and correct for deamination events that would otherwise lease to false-positive results.

FusionPlex Anchored Multiplex PCR (AMP) Chemistry

Learn how the FusionPlex System utilizes Anchored Multiplex PCR chemistry to create target enriched RNA libraries for next-generation sequencing (NGS).

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.